Erythropoiesis-stimulating agentPhase 3 trialInvestigational
Luspatercept
How it works
Stimulates erythropoiesis, the production of red blood cells, to reduce anemia in patients with myelodysplastic syndromes or myeloma.
Cancer types
Leukemia— All patients
Efficacy
In clinical trials, around 50% of patients achieved a hemoglobin response, with a median increase of approximately 1.5 g/dL.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.